Pharmaceuticals, Biotechnology & Life Sciences

Amgen insider Bradway’s $156/share purchase shows confidence in biotech growth and dividend prospects, offering a rare low‑price entry for long‑term investors.

Explore how Ligand Inc.’s insider trades reveal a disciplined investment strategy, market valuation insights, and pipeline potential for oncology and hormone therapies.

Explore how Bicara Therapeutics’ executive Rule 10b‑5 trades align with a growing stock rally, robust pipeline milestones, and strong governance for investors.

Insightful analysis of Madrigal Pharmaceuticals’ insider buying, revealing strong confidence in its small‑molecule cardiovascular pipeline and long‑term value.

Discover how Sionna Therapeutics’ insider buying and selling signals confidence yet reveals market challenges, and what this means for investors and future growth.

Insider buying by Ligand Pharmaceuticals’ chief legal officer shows confidence in a high‑growth, hormone‑targeted biotech amid market volatility and strategic shelf‑offer funding plans.

CEO RSU grant signals confidence in Madrigal’s cardiovascular drug pipeline, hinting at future growth and potentially easing investor volatility.

Explore how General Counsel Kelley Shannon’s RSU grant and insider trade impact Madrigal Pharma’s equity strategy, talent retention, and growth outlook.

Krystal Biotech insider sales raise questions about funding, market‑access timing and competitive positioning in rare‑disease gene‑therapy—what investors need to know.

Revolution Medicines insider trades reveal a strategic shift: CEO sells for liquidity while CFO and others buy, suggesting confidence in an undervalued oncology pipeline.